Adaptimmune Therapeutics plc is rapidly ramping up commercial operations as it launches Tecelra (afamitresgene autoleucel), which is now the first US Food and Drug Administration-approved T-cell receptor (TCR) cell therapy.
The FDA granted Tecelra accelerated approval on 1 August for patients with synovial sarcoma who
Key Takeaways
-
The FDA granted accelerated approval to Adaptimmune’s T-cell receptor therapy Tecelra for synovial sarcoma.
-
The approval marks the first for an engineered cell therapy for a solid tumor and the first major advance in synovial sarcoma for a decade
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?